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SIR, Further to Dr Huaux's letter I would like to make it
clear that I do not challenge in any way the observations
made by his and other groups, nor do I reject the concept
of amyloid induced bone and joint disease in patients
receiving chronic haemodialysis. My criticism is of the
interpretation of the results. The discovery of amyloid in
symptomatic joints of patients undergoing haemodialysis is
not of itself evidence that it is responsible for the
symptoms. Only after adequate control studies have failed
to show the presence of amyloid in asymptomatic but
otherwise adequately matched patients should a possible
pathogenetic link between amyloid and the connective
tissue disorders associated with haemodialysis be pos-
tulated. It is perhaps worth summarising the evidence for
'amyloid arthropathy' and discussing its potential signifi-
cance.
There is a syndrome manifested most frequently by joint
pain or carpal tunnel syndrome, or both, which is a
significant cause of morbidity in patients undergoing long
term haemodialysis. It affects as many as 30% of patients
on dialysis for more than seven years,' and some of its
clinical and radiological manifestations are reminiscent of
the amyloid deposition disease seen in other disorders.
Amyloid is present in many symptomatic sites in this
syndrome but is also recognised to occur in association
with carpal tunnel syndrome in non-dialysed patients2 and
in the joints of asymptomatic dialysis patients. The
amyloid in dialysis patients contains the protein I2 micro-
globulin (f6M),3 increased serum levels of which are found
in patients with renal failure, including patients undergoing
haemodialysis and those receiving continuous ambulatory
peritoneal dialysis.4 Only in haemodialysis patients di-
alysed across conventional cellulose type membranes is the
syndrome encountered.
If f6M amyloid is the cause of the syndrome then
removing it or preventing its accumulation should be the
therapeutic goal. f32M can be removed at dialysis if a highly
permeable dialysis membrane material such as polyacrylo-
nitrile is used instead of the conventional cellulose.5 The
long term use of this membrane may well reduce the
incidence of 'amyloid arthropathy'.'
There is, therefore, circumstantial evidence causally
implicating 02M amyloid in this syndrome. If all the
disparate studies connect in the ways suggested then the
logical therapeutic response would be to change all dialysis
membranes. This has a variety of far reaching implications,
and any decision needs to be based on sound scientific
evidence. In particular, it is mandatory that the basic
premise-amyloid causes the symptoms-is correct. It may
well be, but I am still not convinced that the uncontrolled
studies performed to date are adequate proof of this
connection. Adequate control studies would be simple to
undertake, and until it can be shown that amyloid is not
a universal finding in the joints of patients receiving long
term haemodialysis treatment, use of the term 'amyloid
arthropathy' with all its attendant pathogenetic implica-
tions cannot be justified.
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Amyloid arthropathy in haemo-
dialysed patients
SIR, Two recent letters to the editor in the Annals' about
our paper on amyloid arthropathy in patients undergoing
haemodialysis3 have suggested that the finding of amyloid
in the synovial tissue or fluid, or both, of these patients
could be interpreted as an epiphenomenon related mainly
to aging and osteoarthritis.
We would like to point out the following facts. The
patients presented a rather characteristic picture (persis-
tent swelling of several joints, mainly shoulders, knees,
wrists, finger tenosynovitis, and carpal tunnel syndrome).
Their x rays did not show osteoarthrosis but geodes and
erosions that can lead to a destructive arthropathy, and as
has been reported by other authors4 5 it is possible to
demonstrate amyloid in the bone as well as in the synovial
tissue. In a study that we have just finished we failed to
show amyloid in synovial tissue and synovial fluid in 10 age
matched patients with diverse rheumatic diseases.
These facts make it improbable that aging and osteoar-
throsis were the cause of the amyloid deposition in our
cases, beside the fact that in these other circumstances the
synovial deposits are minimal and, as far as I know, of little
clinical significance.
The tinctorial characteristics of the amyloid, using the
Wright technique, in our cases pointed towards an amyloid
of immunological origin (AL amyloid). Recently the
biochemical nature of amyloid in amyloidosis associated
with haemodialysis has been identified as a protein
homologous with normal plasmatic P2 microglobulin,6
which is known to accumulate in the circulation of patients
with chronic renal failure and because of its size cannot be
removed from the plasma during haemodialysis.
We have started immunohistochemical analysis of the
amyloid found in our patients, and at this stage we have
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preliminary results for ten of them. The amyloid found in
annular ligament and perineural region in three cases and
in fragments of villi of knee synovial fluid sediment in
another seven cases were studied by means of immuno-
histochemical analysis using the peroxidase-antiperoxidase
method, with anti 32 microglobulin antibodies (Dako),
confirming that they contain 12 microglobulin.
As Ian Rowe points out 'although the biochemical
nature of amyloid deposits in osteoarthritic joints has not
been characterised, it should be possible to determine
whether these or any other age related amyloid deposits
contain 12 microglobulin'.7
Until then, and considering all the above mentioned
points, we think that there is no basis for considering that
we are dealing with the same kind of amyloidosis.
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Note
Symposium on antirheumatic
drugs: basis for variability in
response
A satellite meeting of the 10th International Pharmacology
Meeting, Sydney, Australia will be held on 20-22 August,
1987 at Manly Pacific Hotel, Manly, Sydney, Australia.
Details from Professor P Brooks, Department of Rheu-
matology, Royal North Shore Hospital, St Leonards,
Sydney, NSW, Australia 2065.
Correction: Clinical vignette-The 'L4 syndrome' as a
cause of obscure knee symptoms
In this vignette by Drs M I D Cawley and J C Robertson
(Ann Rheum Dis 1986; 45: 704) we regret that a word was
omitted from the first sentence. This should have read 'The
deep pain referral territory (sclerotome) of the fourth
lumbar segment includes the knee and anterior tibial
region.
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